Spyre launches stock sale to fund new SPY072 late-stage program
What's the deal? Spyre TherapeuticsDealroom has a profile for this one. Try Dealroom → (Nasdaq: SYRE) has started an underwritten public offering of common stock to fund its drug pipeline. The clinical-stage biotech said proceeds would help advance its gastroenterology, rheumatology, and dermatology programs, plus a new program to push its SPY072 candidate into late-stage development for hidradenitis suppurativa.
What's the endgame? Spyre develops immunology therapies, including extended half-life antibodies targeting a4p7, TL1A, IL-23, and IL-17A/F. The cash would fund preclinical studies, clinical trials, manufacturing, and Phase 3 readiness across its three therapeutic areas.
Who's involved? JefferiesDealroom has a profile for this one. Try Dealroom →, TD CowenDealroom has a profile for this one. Try Dealroom →, Leerink PartnersDealroom has a profile for this one. Try Dealroom →, and Stifel are joint book-running managers; LifeSci CapitalDealroom has a profile for this one. Try Dealroom → is passive bookrunner. Spyre expects to grant the underwriters a 30-day option to buy an additional 15% of the shares offered.
What could go wrong? The offering remains subject to market and other conditions, with no assurance on size, terms, or timing. The new stock issuance — and the extra 15% option if exercised — would dilute existing shareholders.
The signal: Raising fresh equity to fund Phase 3 readiness marks a transition point for Spyre, moving from early clinical work toward the costly late-stage trials that determine whether its immunology bets pay off.
Read more: stocktitan.net
Image credit: Generated with Gemini
